TED360 Forum

TED360 Forum

Course Chair
Raymond S. Douglas, MD, PhD

Raymond S. Douglas, MD, PhD

Professor of Surgery

Division of Ophthalmology

Director, Orbital and Thyroid Eye Disease Program

Cedars-Sinai Medical Center

Los Angeles, CA


Faculty
Kimberly Cockerham, MD, FACS

Kimberly Cockerham, MD, FACS

Neuro-Ophthalmology, Orbital Disease and Oculofacial Restoration

Private Practice: Senta Clinic, San Diego, CA and Central Valley Eye Medical Group, Stockton, CA

Adjunct Clinical Associate Professor

Byers Eye Institute at Stanford School of Medicine

Palo Alto, CA


Suzanne K. Freitag, MD

Suzanne K. Freitag, MD

Director, Ophthalmic Plastic Surgery

Massachusetts Eye and Ear

Associate Professor, Harvard Medical School

Boston, MA


Andrea Lora Kossler, MD, FACS

Andrea Lora Kossler, MD, FACS

Director, Oculofacial Plastic & Orbital Surgery

Assistant Professor of Ophthalmology

Byers Eye Institute at Stanford University School of Medicine

Palo Alto, CA


Louise A. Mawn, MD, FACS

Louise A. Mawn, MD, FACS

Professor of Ophthalmology and Neurological Surgery

Vanderbilt University Medical Center

Nashville, TN


Christian Nasr, MD, FACP, FACE

Christian Nasr, MD, FACP, FACE

Medical Director – Thyroid Center Endocrinology & Metabolism Institute

Cleveland Clinic

Cleveland, OH


Terry J. Smith, MD

Terry J. Smith, MD

Frederick G.L. Huetwell Professor

Ophthalmology and Visual Sciences

Professor of Internal Medicine

University of Michigan Medical School

Ann Arbor, MI


Prem S. Subramanian, MD, PhD

Prem S. Subramanian, MD, PhD

Professor of Ophthalmology, Neurology, and Neurosurgery

University of Colorado School of Medicine

Vice Chair for Academic Affairs

Division Head, Neuro-Ophthalmology

University of Colorado Sue Anschutz-Rodgers Eye Center

Aurora, CO


Shoaib Ugradar, MD, MRCP, MRCS

Shoaib Ugradar, MD, MRCP, MRCS

Clinical Instructor

The Jules Stein Eye Institute

UCLA

Los Angeles, CA


Sara Tullis Wester, MD, FACS

Sara Tullis Wester, MD, FACS

Professor of Clinical Ophthalmology

Oculofacial Plastic and Reconstructive Surgery

Orbital Surgery and Oncology

Bascom Palmer Eye Institute

University of Miami Miller School of Medicine

Miami, FL


Contact Us

Vindico Medical Education
6900 Grove Road
Thorofare, NJ 08086

Email Us




This continuing medical education activity is provided by
Vindico Medical Education

This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.

Earn CME with ABO CC Part II in-person or virtually

Join us in Newport Beach or via livestream for this full-day, highly interactive program that will review the appropriate use of therapies and strategies for delivering individualized care to patients with thyroid eye disease (TED).


Saturday, March 26, 2022

7:30 – 8:00 am PT
Registration and Breakfast


8:00 am – 4:00 pm PT
CME/ABO CC-certified Activity
Lunch to be provided.


Register for In-person!
Register for Virtual!

NEW LOCATION – Hyatt Regency Newport Beach

1107 Jamboree Road | Newport Beach, CA 92660

Topics

  • Differential Diagnosis
  • Exploring TED Pathogenesis
  • Medical Treatment Trends in TED Management
  • Benefit/Risk Profile of Targeted IGF-1R Therapy
  • Research on TED, Therapeutic Targets, and Investigational Therapies
  • Surgical Trends in TED Management
  • New TED Abstracts
  • TED Case Challenges
  • Collegial Conversations and Insights
Download Full Agenda
motionmailapp.com

Overview

TED is a multifactorial, autoimmune disorder with a wide spectrum of signs and symptoms. It is frequently misdiagnosed, due to both the heterogeneous clinical presentation and a failure to understand the relationship between TED and hyperthyroidism. Misdiagnosis can place patients at increased risk for complications; however, a differential diagnosis can be achieved with the assistance of imaging, and early diagnosis and treatment may limit disfigurement and reduce vision loss. Ophthalmologists, oculoplastic surgeons, ophthalmic plastic and reconstructive surgeons, neuro-ophthalmologists, and endocrinologists should be knowledgeable about the conventional and new therapies available for the treatment of patients with TED and how to apply this information into practice. While new information on TED continues to be published and presented, there is a need for an educational forum that addresses the gamut of its management.

The full-day, live, hybrid TED360 Forum aims to provide health care professionals with guidance on the appropriate use of therapies and strategies for delivering individualized care to patients with TED. In this case-based program, expert faculty discuss the available treatment options, and they will review the ongoing research in TED, surgical trends, and targeted insulin-like growth factor 1 receptor (IGF-1R) therapy. The program will also provide a venue in which treaters can openly discuss and address, in a collegial fashion, the latest advances in terms of knowledge about TED pathogenesis, diagnosis, and management options. The TED360 Forum will incorporate didactic presentations, collegial conversations, interactive case challenges, as well as live question-and-answer sessions.

Target Audience

The intended audience for this activity is oculoplastic surgeons, ophthalmic plastic and reconstructive surgeons, neuro-ophthalmologists, endocrinologists, ophthalmologists and other health care professionals involved in the management of patients with TED.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the etiology, pathogenesis, and risk factors for TED to better understand why early diagnosis can improve outcomes in patients.
  • Examine current guidelines and best practices that can improve the diagnosis of TED so that early treatment can be initiated.
  • Assess the safety and efficacy of current medical treatments that can improve the management of patients with TED.
  • Evaluate the benefit/risk profile of IGF-1R therapy and how it may be incorporated into practice, safely and effectively.
  • Describe conventional and novel surgical and aesthetic procedures that have improved overall outcomes in patients with TED.
  • Explore current research about the disease state and investigational therapies that may potentially improve the treatment of TED.
  • Summarize new research that examines how concepts and clinical trial designs for TED studies and its management can become a reality.
  • Examine case presentations, clinical findings, and management solutions that may improve overall outcomes for patients with TED.